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In establishing a genetic diagnosis in heterogeneous neurological disease, clinical 
characterization and whole exome sequencing (WES) go hand-in-hand. Clinical data 
are essential, not only to guide WES variant selection and define the clinical severity 
of a genetic defect but also to identify other patients with defects in the same gene. 
In an infant patient with sensorineural hearing loss, psychomotor retardation, and epi-
lepsy, WES resulted in identification of a novel homozygous CLPP frameshift mutation 
(c.21delA). Based on the gene defect and clinical symptoms, the diagnosis Perrault 
syndrome type 3 (PRLTS3) was established. The patient’s brain-MRI revealed specific 
abnormalities of the subcortical and deep cerebral white matter and the middle blade of 
the corpus callosum, which was used to identify similar patients in the Amsterdam brain-
MRI database, containing over 3000 unclassified leukoencephalopathy cases. In three 
unrelated patients with similar MRI abnormalities the CLPP gene was sequenced, and 
in two of them novel missense mutations were identified together with a large deletion 
that covered part of the CLPP gene on the other allele. The severe neurological and 
MRI abnormalities in these young patients were due to the drastic impact of the CLPP 
mutations, correlating with the variation in clinical manifestations among previously 
reported patients. Our data show that similarity in brain-MRI patterns can be used to 
identify novel PRLTS3 patients, especially during early disease stages, when only part of 
the disease manifestations are present. This seems especially applicable to the severely 
affected cases in which CLPP function is drastically affected and MRI abnormalities are 
pronounced.
Keywords: genetic diagnosis, brain-Mri, Perrault syndrome type 3, Perrault syndrome, CLPP
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inTrODUcTiOn
For identification of the genetic causes of clinically and genetically 
heterogeneous neurological disease, whole exome sequencing 
(WES) has become the prime method of investigation as a rapid, 
single test. Especially for conditions that can be caused by a large 
number of candidate genes, WES provides an unbiased approach 
to identify the genetic cause, precluding comprehensive analysis 
of all individual genes (1–4). By contrast, in some neurological 
conditions, clinical symptoms or additional investigations may 
directly point to one or a few candidate genes, enabling faster 
and cheaper diagnosis by targeted gene analysis (5–7). In practice, 
clinical characterization and WES go hand-in-hand (8, 9). Clinical 
data are essential not only to guide WES variant selection but also 
to define the impact and severity a genetic defect may have.
We investigated a patient in whom MRI and WES studies 
enforced each other in interpreting the genetic defect and 
establishing a diagnosis. We found that in this case MRI data are 
predictive for the severity of the clinical manifestations and can 
be used to identify severe cases of Perrault syndrome due to CLPP 
mutations.
MaTerials anD MeThODs
study Design
We performed WES on a patient (patient 1.1) from consanguine-
ous parents who suffered from pronounced neurological prob-
lems and had specific abnormalities on brain-MRI, comparable 
to his affected sibling (patient 1.2). Subsequently, the Amsterdam 
brain-MRI database containing over 3000 unclassified leukoen-
cephalopathy cases was checked manually by experts to identify 
patients with a similar MRI pattern. This resulted in selection 
of three unrelated patients (patient 2, patient 3.1, and patient 4) 
who were then, together with their affected siblings (patient 3.2), 
subject to targeted CLPP gene analysis.
MeTc
Procedures involving human participants were in accordance 
with the ethical standards of the institutional (MUMC+, VUmc) 
research committee. All subjects gave written informed consent 
in accordance with the Declaration of Helsinki.
Patients
The clinical details of the patients with CLPP mutations were 
retrospectively reviewed.
Magnetic resonance imaging
For all patients, at least one MRI was available for review. The 
studies had been performed on different MRI machines of differ-
ent vendors, precluding quantitative measurements, but allowing 
MRI pattern analysis. In all patients, axial T2-weighted images 
were used for systematic analysis of the abnormalities (10). Based 
on the MRI findings in the first patient, the MRI criteria for fur-
ther inclusion of patients were signal abnormalities in the deep 
and subcortical cerebral white matter, signal abnormalities in the 
middle blade of the corpus callosum, and absence of abnormali-
ties in basal nuclei and thalami.
homozygosity Mapping
Peripheral blood DNA was prepared and labeled for Affymetrix 
Human Mapping 250  K array according to the manufacturer’s 
protocol (Affymetrix GeneChip, Santa Clara, CA, USA).
Wes analysis
Agilent SureSelect version 4 (Agilent Technologies, Santa 
Clara, CA, USA) was used for exome enrichment, and massive 
parallel sequencing was performed on an Illumina HiSeq2000 
platform, using a 2 × 100 bp paired end setting (Illumina, San 
Diego, CA, USA). Exome data of proband 1.1 were filtered for 
homozygous variants in homozygosity regions. Only variants 
with allele frequencies lower than 1% (dbSNP137), consist-
ing of non-synonymous substitutions, INDELs (in-frame and 
frameshift), nonsense mutations, and splice-variants were 
evaluated. Non-annotated variants were maintained, unless 
allele frequencies exceeded 5% prevalence in our in-house patient 
database. Enrichment for missense variants in conserved protein 
domains was ensured by removal of variants with PhyloP values 
<3.5. Pathogenicity of non-synonymous missense mutations was 
estimated by PolyPhen-2 (11), SIFT (12), PROVEAN (13), and 
Mutation Taster (14).
sanger sequencing and Paternity Testing
CLPP exons and flanking intronic regions were PCR amplified 
using M13-tailed primers (Table S1 in Supplementary Material) 
and sequenced by the ABI 3730 automatic sequencer (Applied 
Biosystems, Foster City, CA, USA). CLPP Sanger sequencing was 
performed in all patients, sibs, and parents. Paternity was tested 
by multiplex VNTR analysis using the AmpFISTR Identifiler PCR 
amplification kit according to manufacturer’s manual (Applied 
Biosystems, Foster City, CA, USA).
CLPP mrna expression
RNA was isolated from patient and control skin fibroblasts using 
the MagMAX-96 Total RNA Isolation Kit (ThermoFisher sci-
entific, Waltham, MA, USA). cDNA was synthesized by qScript 
cDNA Synthesis Kit (Quanta Biosciences, Gaithersburg, MD, 
USA) using 1 μg RNA input. mRNA expression was measured by 
the 7900HT Fast Real-Time PCR System (Applied Biosystems, 
Foster City, CA, USA) based on a primer pair at the 5′ side 
(exon 2 and 3, 104-bp amplicon) and 3′ side (exon 5 and 6, 
170-bp amplicon) of the CLPP transcript (NM_006012). CLPP 
expression was normalized against the TBP housekeeping gene 
(TATA box-binding protein, NM_003194, primer set in exon 5 
and 6, 89-bp amplicon) (Table S1 in Supplementary Material). 
Sensimix Sybr Hi-Rox (Bioline, Taunton, MA, USA) was used 
for cDNA amplification, and a relative CLPP mRNA expression 
was calculated using the 2−ΔΔCt method, normalizing to healthy 
control fibroblasts. Statistical significance was calculated using a 
T-TEST (one-tailed, two-sample equal variance) with Bonferroni 
correction.
Protein structure Modeling
An X-ray structure of the human mitochondrial CLPP heptamer 
(PMID: 15522782) at 2.10  A resolution has been used for 
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visualizing mutations in the protein structure. The structure was 
displayed in PyMol (ver.1.8), and mutations were introduced with 
the Mutalizer package.
mtDna and CLPP copy number 
Quantification
mtDNA copy number was quantified by comparing mtDNA 
encoded ND5 copy number (mtDNA NADH dehydrogenase 5, 
NC_012920.1) with the nuclear B2M gene (nuclear gene beta-
2-microglobulin, NC_000015.10) (Table S1 in Supplementary 
Material). DNA amplification was performed under similar 
conditions as reported above. A relative mtDNA copy number 
was defined using the 2−ΔΔCt method, normalizing to heathy 
control fibroblasts. Statistical significance was calculated using a 
T-TEST (one-tailed, two-sample equal variance) with Bonferroni 
correction.
A similar method was used to determine the CLPP nDNA 
copy number (NC_000019.10). A primer pair located in intron 
2 and exon 3 (primer set exon 3, 176-bp amplicon) and in intron 
5 and exon 6 (primer set exon 6, 168-bp amplicon) of the CLPP 
gene were used. Two amplicons were designed to cover part of 
exon 4, a primer pair in intron 3 and exon 4 (primer set 4A; 
135bp amplicon), and exon 4 and intron 4 (primer set 4B; 164bp 
amplicon) (Table S1 in Supplementary Material).
resUlTs
Patients
Table S2 in Supplementary Material contains the clinical details 
of all patients. The proband, patient 1.1 (born in 1993), was the 
second child from consanguineous parents. He presented with 
congenital sensorineural deafness, psychomotor retardation, 
epilepsy, and small stature. He had a younger brother, patient 1.2 
(born in 1995), with a similar clinical picture. Patient 2 (born in 
1994) and sibling-patients 3.1 and 3.2 (born in 1989 and 1994, 
respectively) also had early onset deafness, stunted growth, devel-
opmental retardation of variable severity, and motor problems 
due to ataxia, spasticity, and peripheral neuropathy. Two of the 
patients had epilepsy. In all patients, the disease course was slowly 
progressive and in some of them provoking factors like febrile 
infections could lead to episodes of regression.
Magnetic resonance imaging
Table 1 contains the MRI details of all patients, also illustrated in 
Figure 1. All patients had inhomogeneous, partially multifocal, 
and partially confluent signal abnormalities in the deep and sub-
cortical white matter, largely sparing the directly periventricular 
white matter. In all patients, the middle blade of the corpus cal-
losum was affected, while the inner and outer blades were spared. 
Only one patient (patient 2) showed signal abnormalities in the 
cerebellar white matter and central tegmental tracts in the pons, 
while two patients had signal abnormalities in the middle cer-
ebellar peduncles. Over time, cerebral and less severe cerebellar 
atrophy occurred.
Patient 4, who did not have CLPP mutations, had more exten-
sive cerebral white matter abnormalities at disease onset and 
striking swelling of the corpus callosum. In the course of a few 
years, the white matter signal abnormalities largely disappeared, 
although the middle blade of the corpus callosum remained 
abnormal. He developed very mild atrophy.
Wes and CLPP analysis
Whole exome sequencing of patient 1.1 (family 1) resulted, 
after filtering, in 34 homozygous variants. His brother, patient 
1.2, was affected as well and homozygosity mapping showed a 
56-Mb overlap between the siblings, resulting in 19 candidate 
genes. Candidate mutations were further limited to evolution-
ary conserved protein positions. The most promising mutation 
was a novel (non-annotated) homozygous mutation in a highly 
conserved domain of the CLPP gene (NM_006012_c.21delA, 
chr: 19, g.6361606delA). The single nucleotide deletion is 
located in exon 1 and is expected to cause a frameshift with a 
nonsense mutation in exon 3 [p.(Ala10Profs*117)]. The result-
ing “stop” mutation would cause a loss of 160 amino acids of 
the evolutionary highly conserved CLPP protein and is likely 
to result in nonsense mediated mRNA decay. Indeed, CLPP 
mRNA expression was decreased to approximately 50% in 
patient fibroblasts compared to control fibroblasts (Figure 2A), 
confirming a role for nonsense-mediated decay. As it has been 
reported in mice studies that CLPP mutations affect mtDNA 
copy number, we determined this in fibroblast DNA from 
patient 1.1 (15). Patient 1.1 showed an approximately three-
fold increase in mtDNA copy number (Figure 2B). Mutation 
segregation testing in family 1 indicated that the unaffected 
parents and sister were heterozygous, and the affected brother 
was homozygous for the variant.
Patient 2 (family 2) carried an apparently homozy-
gous c.484G  >  A (NM_006012.2_ c.484G  >  A; chr: 19; 
g.6364579G >  A) missense mutation in exon 4, causing an 
amino acid substitution at p.(Gly162Ser), which is located 
at the border of a helix domain (p.154–160; Nextprot: EC 
3.4.21.92). The mutation affects an evolutionary conserved pro-
tein domain (PhyloP: 5.61) and was predicted harmful at the 
protein level (SIFT: 0.000, PROVEAN: −5.8, MutationTaster: 
disease causing). To examine the impact of the p.(Gly162Ser) 
amino acid substitution on CLPP protein structure, template-
based in silico protein modeling was performed based on the 
crystal structure of the CLPP heptamer (UNIPROT accession 
number: Q16740, Protein Data Bank identifier 1tg6). The 
p.(Gly162Ser) mutation in our patient introduces a bulky 
serine side chain that destabilizes the interaction between two 
structural domains, the alpha-helix (residues 154–160) and the 
beta sheet (residues 143–152) (Figure 3A). More importantly, 
the serine side chain protrudes toward and clashes with the 
Thr145 amino acid of the beta sheet, a residue in which the 
p.(Thr145Pro) mutation, resulting in significant disruption of 
the protein structure in the region, has been reported as disease 
causative (16). Segregation analysis in the family indicated that 
patient 2 was hemizygous for the mutation, as the father was 
heterozygous carrier and the mother did not carry the mutation 
(wild-type). To test for the presence of a maternal deletion, we 
determined the CLPP copy number for regions in exon 3, 4, and 
6 in the patient and his parents. The patient’s copy number was 
TaBle 1 | Mri findings.
Patient number Patient 1.1 Patient 1.2 Patient 2 Patient 3.1 Patient 3.2
Year of birth 1995 1993 1994 1989 1994
Mris (ages in years) 2 (9, 10, 12) 1 (8) 4 (3, 11, 12, 17, 20) 2 (11, 20) 1 (4)
First Mri
Cerebral WM abn.a, aspect Inhomogeneous, 
partially multifocal
Multifocal Inhomogeneous, partially 
multifocal
Inhomogeneous, partially 
multifocal
Inhomogeneous, 
partially multifocal
Predominance cerebral WM abn. Deep + subcortical Deep Deep + subcortical Deep + subcortical Deep + subcortical
Sparing cerebral WM Periventricular Periventricular + subcortical Periventricular Periventricular Periventricular
Corpus callosum genu abn. +, esp. middle blade +, middle blade +, esp. middle blade +, esp. middle blade +, esp. middle blade
Corpus callosum body abn. − − − − −
Corpus callosum splenium abn. + +, middle blade + − +
Internal/external capsule abn. −/− −/− −/− −/− −/−
Swelling of abn. WM − − − − −
Rarefaction of abn. WMb − − + − −
WM cystsc − − − − −
Cerebral cortex signal abn. − − − − −
Basal nuclei signal abn. − − − − −
Thalamus signal abn. − − − − −
Cerebral atrophy Slight − − Slight −
Cerebellar WM signal abn. − − + − −
Hilus dentate nucleus abn. − − − − −
Cerebellar cortex signal abn. − − − − −
Dentate nucleus signal abn. − − − − −
Cerebellar atrophy − − − − −
Middle cerebellar peduncles abn. − + + − −
Brainstem signal abn. − − +, central tegmental tracts − −
Brain stem atrophy − − − − −
Contrast enhancement − n.d. n.d. n.d. n.d.
Restricted diffusiond n.d. n.d. n.d. n.d. n.d.
Elevated lactate in MRS − n.d. n.d. n.d. n.d.
latest Mri
Change over time Slight further 
cerebral atrophy
Cerebral and cerebellar 
atrophy; no diffusion 
restriction; no contrast 
enhancement
Cerebral and cerebellar 
atrophy, cerebellar 
WM abn., no diffusion 
restriction
−
aSignal abnormalities defined as an abnormally high signal on T2-weighted images.
bWhite matter rarefaction defined as T2-hyperintense WM with low signal on FLAIR, but not as low as cerebrospinal fluid.
cCysts defined as T2-hyperintense WM with low signal on FLAIR, as low as cerebrospinal fluid.
dRestricted diffusion assessed using the apparent diffusion coefficient (ADC) to avoid T2-shine-through effects.
WM, white matter; abn., abnormalities/abnormal; MRS, magnetic resonance spectroscopy; n.d., not done; esp., especially; +, present; −, absent; FLAIR, fluid-attenuated inversion 
recovery.
4
Theunissen et al. MRI Abnormalities Reveal PRLTS3
Frontiers in Neurology | www.frontiersin.org November 2016 | Volume 7 | Article 203
approximately 50% lower for exon 3 and exon 4 compared to 
the father (Figure 4A). The same decrease in copy number was 
seen in DNA from the mother and healthy sibling, indicating 
that the deletion was inherited from the mother. Interestingly, 
the copy number of exon 6 did not significantly differ, which is 
in line with the presence of a heterozygous SNP in exon 6 of the 
patient. The maternally inherited deletion is therefore expected 
not to exceed exon 6.
In patient 3.1 and his affected brother patient 3.2 (family 3), an 
apparently homozygous c.425C > T (NM_006012.2_ c.425C > T; 
chr: 19; g.6364520C > T) missense mutation was identified in exon 
4, in an evolutionary highly conserved protein domain (PhyloP: 
5.69). It was predicted to have highly pathogenic impact on 
protein function (SIFT: 0.003, PROVEAN: −8.9, MutationTaster: 
disease causing). The resulting p.(Pro142Leu) amino acid 
substitution is located at the border of a Beta-strand (p.143–152; 
Nextprot: EC 3.4.21.92), near two mutations [p.(Thr145Pro) and 
p.(Cys147Ser)] that have been included in the HGMD database 
for disease-causing mutations. The p.(Pro142Leu) mutation 
changes a non-reactive proline residue, located in a loop 
(139–142) at the boundary with the beta sheet (143–152), into 
a highly hydrophobic leucine residue (Figure 3B). This loop is 
localized at the CLPP–CLPX interface that is mediated by the beta 
sheet structure shown to be affected by the previously reported 
Thr145Pro mutation and p.(Gly162Ser) mutation, reported here 
for patient 2. Likely, the drastic hydrophobicity change, caused 
by the p.(Pro142Leu) mutation, will affect the efficiency of 
CLPP–CLPX docking due to changes at the CLPP–CLPX inter-
face, a region in which mutations have previously been related to 
pathogenicity (16). Segregation testing showed that his affected 
FigUre 1 | Mri of patient 1.1 at 9 years (a–D) and 12 years (e–h). 
The first MRI shows signal abnormalities in the middle blade of the corpus 
callosum [(a,c) and inset in (a)]; inhomogeneous mainly multifocal signal 
abnormalities in the subcortical and deep cerebral white matter, sparing a 
periventricular rim (c,D); and slight cerebral (c,D) but no cerebellar atrophy 
(a,B). At follow-up, slightly increased cerebral and cerebellar atrophy is seen. 
Mri of patient 2 at 4 years (i–l) and 20 years (M–P). The first MRI shows 
signal abnormalities in the middle blade of the corpus callosum (i,K), 
inhomogeneous, mainly confluent signal abnormalities in the subcortical and 
deep cerebral white matter, sparing a periventricular rim (K,l) and no 
cerebral or cerebellar atrophy (i–l). At follow-up, severe cerebral and milder 
cerebellar atrophy is seen (M–P). The corpus callosum is highly atrophic, but 
the selective involvement of the middle blade is still seen [inset in (O)]. Within 
the posterior fossa, signal abnormalities are present in the middle cerebellar 
peduncles and pontine central tegmental tracts (n).
FigUre 2 | (a) CLPP mRNA expression was measured using a primer pair at the 3′ side (exon 2 and 3) and 5′ side (exon 5 and 6) of the transcript (NM_006012) 
and was normalized to TBP. Approximately 50% lower CLPP mRNA levels were found in patient 1.1 fibroblasts compared to controls. (B) mtDNA copy number was 
measured based on ND5 copy number and was normalized to nuclear B2M. Approximately a threefold copy number increase was measured in patient 1.1 
(proband) fibroblasts compared to control fibroblasts.
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sibling carried the same mutation and that both patients were 
hemizygous, since only the mother was a heterozygous carrier, 
whereas the father did not carry the mutation. Non-paternity was 
excluded. CLPP copy numbers for regions in exon 3, 4, and 6 
were determined for patient 3.1 and his parents (Figure 4B). An 
approximately 50% decrease in copy number of exon 3, exon 4, 
and exon 6 was observed in the patient and his father, but not 
his mother. The genomic deletion, which is transmitted by the 
father, is therefore expected to cover at least exon 3 to exon 6 of 
the CLPP gene.
In patient 4, no mutations were identified in the CLPP gene.
DiscUssiOn
Using WES, we identified a novel homozygous single nucleotide 
deletion (c.21delA) in the CLPP gene of two affected siblings of 
family 1. The resulting frameshift was expected to introduce a pre-
mature stop codon in exon 3. Quantification of CLPP transcript 
expression in patient fibroblasts showed an approximately 50% 
decrease in CLPP mRNA levels, indicating nonsense-mediated 
decay. CLPP plays a role in the mitochondrial unfolded protein 
response pathway (mtUPR) by multimerizing with the CLPX 
chaperone within the mitochondrial matrix, thereby forming 
a proteasome-like cylinder that is capable of hydrolyzing mito-
chondrial proteins into small peptides. It is therefore expected 
to react upon protein conformational stress in mitochondria 
by inducing mitochondrial stress signaling pathways (17, 18). 
Molecular characterization of Clpp null mice has demonstrated 
that the absence of Clpp transcripts leads to significant increases 
in mtDNA copy number in several tissues (testis, ovary, heart, and 
brain) (15). We confirmed an approximately threefold increase in 
mtDNA copy number in fibroblasts of patient 1.1, indicating that 
the c.21delA mutation was likely to affect CLPP function in the 
same way.
We used the brain-MRI of patient 1.1 as a template to screen 
an Amsterdam brain-MRI database containing over 3000 unclas-
sified leukoencephalopathy for comparable characteristics and 
selected three patients based on similarities in brain-MRI and 
FigUre 3 | crystal structure-based in silico modeling of the clPP 
protein (Uniprot accession number: Q16740). (a) p.(Gly162Ser) 
introduces a long serine side chain that interacts with the Thr145 amino acid 
and destabilizes the interaction between the alpha-helix structure (residues 
154–160) and beta sheet (residues 143–152). Red disks indicate significant 
van der Waals overlap, including a conflict with a p.145 position previously 
reported in CLPP patients. (B) p.(Pro142Leu) changes a proline residue, 
located in a loop (139–142) at the boundary with a beta sheet (143–152), into 
a highly hydrophobic Leucine residue. This drastic hydrophobicity change 
could interfere with CLPP–CLPX binding at the interface.
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clinical manifestations for targeted CLPP sequencing (19). In 
two of these patients, we identified harmful missense mutations 
in CLPP. In the third patient, no CLPP mutation was identified. 
This patient initially fulfilled the MRI criteria, but over the years, 
the white matter abnormalities improved and largely disappeared 
without significant cerebral or cerebellar atrophy. A p.(Gly162Ser) 
mutation in patient 2 and p.(Pro142Leu) mutation in patient 3.1 
and 3.2 were located at an evolutionary highly conserved amino 
acid position and were predicted to be pathogenic according to 
several in silico prediction tools. Crystal structure-based protein 
modeling showed that the p.(Gly162Ser) mutation is likely to 
destabilize the interaction between an alpha-helix structure and 
beta sheet and could therefore disrupt CLPP protein structure. 
The mutation interferes with the amino acid p.Thr145, a residue 
in which a disease-causing mutation was previously reported in 
a patient with pronounced neurological symptoms (Table  2). 
Also, changes in hydrophobicity of the p.(Pro142Leu) substitu-
tion, located adjacent to this beta sheet, could interfere with the 
CLPP–CLPX binding-interface (20). Changes at the CLPP–CLPX 
interface have previously been suggested to be involved in disease 
(16). CLPP copy number quantification in fibroblasts of patient 2 
and patient 3.1 showed that both mutations were actually hemizy-
gous. Whereas the CLPP deletion in patient 2 was maternally 
inherited and did not exceed exon 6, the deletion in patient 3.1 
was paternally inherited and covered at least exon 1 to 6. Our data 
indicate that large deletions can be responsible for a substantial 
part of the inherited CLPP defects and that one should be aware 
that these mutations could be missed in purely sequencing-based 
approaches.
Our patients, who were all males, suffered from heterogene-
ous manifestations, involving congenital sensorineural hearing 
loss (SNHL), psychomotor retardation, ataxia, autism, epilepsy, 
and short stature. Comparable symptoms have previously been 
reported in seven other families with CLPP defects (Table 2) (16, 
21–24). Apart from the consistent involvement of SNHL, sex-
related clinical features have been reported such as female ovarian 
dysgenesis and infertility due to azoospermia in males (15, 22). 
Our male patients were not tested for infertility. Consequently, 
CLPP mutations cause highly heterogeneous symptoms that 
have been classified as Perrault syndrome type 3 (PRLTS3). 
T2-weighted brain-MRI of our patients showed inhomogeneous 
signal abnormalities in the deep and subcortical cerebral white 
matter and middle blade of the corpus callosum, with over time 
severe cerebral atrophy. However, neurological implications are 
not always pronounced in PRLTS3. Whereas two earlier reported 
families showed severe neurological symptoms and white matter 
abnormalities on MRI, other families showed a much milder phe-
notype. Previously, Jenkinson et al. explained differences in clini-
cal impact by the more drastic structural protein changes caused 
by the p.(Thr145Pro) mutation in comparison to p.(Cys147Ser). 
The c.270 + 4A > G splice site mutation was shown to cause only 
partial ablation of donor splice site function and was therefore 
likely to have residual CLPP activity (Table  2) (16). Our data 
support the observation that severe neurological PRLTS3 phe-
notypes are caused by mutations that drastically affect the native 
CLPP protein structure and show that large deletions might be 
responsible for a substantial part of these CLPP defects.
Whereas symptoms such as SNHL might manifest during 
early childhood with gradual progression and variable impact, 
indications for infertility such as impaired sex hormone profiles 
can only be detected after puberty. Age-dependent symptom 
FigUre 4 | The clPP nDna copy number was determined based on amplicons in exon3, exon 4, and exon 6 and was normalized to B2M. Copy 
numbers were relative to control DNA. (a) In family 2, CLPP copy numbers of patient 2, the healthy sibling, and mother were compared to the heterozygous father 
and indicated a maternally inherited CLPP deletion. (B) In family 3, CLPP copy numbers of patient 3.1 and the father were compared to the heterozygous mother 
and indicated a paternally inherited CLPP deletion.
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presentation and phenotypic heterogeneity can therefore impede 
genetic diagnosis, especially during early disease onset when only 
part of the disease manifestations is present. We demonstrate that 
similarity in brain-MRI pattern of abnormalities among patients 
can be successfully used to identify other PRLTS3 patients, 
already at early disease onset. Our selection criteria were signal 
abnormalities predominantly involving both the subcortical and 
deep cerebral white matter and the middle blade of the corpus 
callosum. Multifocal and confluent abnormalities predominantly 
involving the subcortical and deep cerebral white matter, sparing 
a periventricular rim, are also seen in l-2-hydroxyglutaric aci-
duria, Kearns Sayre syndrome, and ‘Leukoencephalopathy with 
thalamus and brain stem abnormalities and lactate elevation’ and 
Canavan disease (19, 25). However, involvement of the subcorti-
cal and deep cerebral white matter is typically associated with 
sparing of the corpus callosum or involvement of its outer blade. 
The combination of abnormalities predominantly involving the 
subcortical and deep cerebral white matter and the middle blade 
of the corpus callosum is so specific for PRLTS3 that it allowed 
us to select patients by MRI criteria only. However, since not 
all PRLTS3 patients suffer from neurological symptoms, this 
approach may only apply to severely affected cases.
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TaBle 2 | indicates the neurological implications of clPP mutations in our patients (family 1–3) and earlier reported clPP cases (family 4–10).
 Family Pronounced neurological symptoms White matter abnormalities (Mri) Mutations
1 consanguineous (patient 1.1 and 1.2) Yes Yes • NM_006012_c.21delA (homozygous)
• frameshift with nonsense mutation
• NMD: 60% transcript loss
2 non-consanguineous (patient 2) Yes Yes • NM_006012.2_c.484G > A
• p.(Gly162Ser) (hemizygous)
• large allelic CLPP deletion
3 non-consanguineous (patient 3 and 3.1) Yes Yes • NM_006012.2_c.425C > T
• p.(Pro142Leu) (hemizygous)
• large allelic CLPP deletion 
literature reported
4 consanguineous (3 patients) Yes; the 8-month-old boy did not show 
signs of PRLTS3 yet
Yes (eldest sibs) • c.685T > G
• p.(Tyr229Asp) (homozygous)
5 consanguineous (3 patients) Yes Yes (single patient analyzed) • c.433A > C
• p.(Thr145Pro) (homozygous)
6 consanguineous (4 patients) No n.d. • c.440G > C
• p.(Cys147Ser) (homozygous)
7 consanguineous (2 patients) No n.d. • c.439T > A
• p.(Cys147Ser) (homozygous)
8 consanguineous (3 patients) No n.d. • c.270p(+)4A > G (homozygous)
• splice donor site mutation
• weakens donor splice site function 
9 consanguineous (1 patient) No No • c.430T > C
• p.(Cys144Arg) (homozygous)
10 unknown (ahead of print) (2 patients) No n.d. • c.624C > G
• p.(Ile208Met) (homozygous)
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